Eveline E Vietsch
Overview
Explore the profile of Eveline E Vietsch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
544
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Eijck C, Ju J, van t Land F, Verheij M, Li Y, Stubbs A, et al.
Pancreatology
. 2024 Sep;
24(7):1057-1065.
PMID: 39218754
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Presently, only a fraction of patients undergo successful surgical resection, the most effective treatment. Enhancing treatment strategies...
2.
Vietsch E, Latifi D, Verheij M, van der Oost E, de Wilde R, Haen R, et al.
Front Immunol
. 2023 Nov;
14:1230306.
PMID: 38022530
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest solid tumors and is resistant to immunotherapy. B cells play an essential role in PDAC progression and immune responses, both locally...
3.
van Eijck C, Strijk G, Vietsch E, van der Sijde F, Verheij M, Mustafa D, et al.
Eur J Cancer
. 2023 Nov;
196:113440.
PMID: 37988843
Background: FOLFIRINOX chemotherapy has improved outcomes for pancreatic cancer patients, but poor long-term survival outcomes and high toxicity remain challenges. This study investigates the impact of FOLFIRINOX on plasma proteins...
4.
van der Sijde F, Dik W, Mustafa D, Vietsch E, Besselink M, Debets R, et al.
Front Immunol
. 2022 Sep;
13:898498.
PMID: 36091056
Background: Biomarkers predicting treatment response may be used to stratify patients with pancreatic ductal adenocarcinoma (PDAC) for available therapies. The aim of this study was to evaluate the association of...
5.
Martinez Roth S, Vietsch E, Barefoot M, Schmidt M, Park M, Ramesh A, et al.
Gastrointest Disord (Basel)
. 2022 May;
3(3):100-112.
PMID: 35531260
Thoracic high dose radiation therapy (RT) for cancer has been associated with early and late cardiac toxicity. To assess altered rates of cardiomyocyte cell death due to RT we monitored...
6.
Peran I, Vietsch E, Yan G, Riegel A, Wellstein A
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326668
Pancreatic adenocarcinoma is typically detected at a late stage and thus shows only limited sensitivity to treatment, making it one of the deadliest malignancies. In this study, we evaluate changes...
7.
Lin Y, Schmidt M, Sharif G, Vietsch E, Kiliti A, Barefoot M, et al.
Oncoimmunology
. 2022 Feb;
11(1):2027136.
PMID: 35127250
Pancreatic cancer remains largely unresponsive to immune modulatory therapy attributable in part to an immunosuppressive, desmoplastic tumor microenvironment. Here, we analyze mechanisms of cancer cell-autonomous resistance to T cells. We...
8.
van der Sijde F, Homs M, van Bekkum M, van den Bosch T, Bosscha K, Besselink M, et al.
Int J Mol Sci
. 2021 Oct;
22(20).
PMID: 34681562
In this study, we explored the predictive value of serum microRNA (miRNA) expression for early tumor progression during FOLFIRINOX chemotherapy and its association with overall survival (OS) in patients with...
9.
van der Sijde F, Mustafa D, Vietsch E, Katsikis P, van Eijck C
Pancreas
. 2021 Oct;
50(7):933-941.
PMID: 34643608
To date, little advances have been made toward new and more effective therapies for pancreatic ductal adenocarcinoma (PDAC). Discovery of prognostic and predictive biomarkers is needed to stratify patients for...
10.
Farshadi E, Chang J, Sampadi B, Doukas M, Van t Land F, van der Sijde F, et al.
Clin Cancer Res
. 2021 Sep;
27(23):6602-6612.
PMID: 34580113
Purpose: We investigated whether organoids can be generated from resected tumors of patients who received eight cycles of neoadjuvant FOLFIRINOX chemotherapy before surgery, and evaluated the sensitivity/resistance of these surviving...